Merck & Co has said it will not file its cholesterol drug anacetrapib with regulators, saying that trial results are not good enough for clinical filings. The news came in a brief statement ...

Merck is taking steps to suspend the availability of its cholesterol drug, Tredaptive tablets worldwide, following a recommendation from European regulators. Tredaptive (extended-release niacin ...

A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

Merck’s monopoly on a blockbuster diabetes drug that has generated about $50 billion in global sales seemed like it might be ...

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...

Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...